Janssen Submits Supplemental New Drug Application for Zytiga to Treat Metastatic Prostate Cancer

Janssen Submits Supplemental New Drug Application for Zytiga to Treat Metastatic Prostate Cancer
Janssen Biotech seeks U.S. approval to use a triple combination treatment with Zytiga (abiraterone acetate), prednisone and androgen deprivation therapy (ADT) for men with high-risk metastatic hormone naïve prostate cancer (HNPC) or newly diagnosed, high-risk metastatic hormone sensitive prostate cancer (HSPC). As such, the Danish pharmaceutical giant submitted a supplemental New Drug Application (sNDA) to the U.S. Food and

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *